The World Health Organization estimates that 33.4 million people worldwide are HIV positive. Approximately 22.4 million people living in sub-Saharan Africa are HIV positive. Those infected & affected by HIV are at their most productive age between (15 – 49 years).  This has detrimental effects on economic growth and stability of the region.

PAAL partnered with international donor companies to develop and implement workplace HIV/AIDS policies for large private sector and parastatal organizations under the IMPACT project.

PAAL works closely with a number of employers to develop workplace HIV/AIDS policies. This program encourages employers to provide anti-retroviral therapy to their employees.  PAAL also negotiated preferential or access prices for anti-retrovirals for national and workplace programs. These prices, at one time were around 5 percent of the prices for the same brands in the developed world. Generic products, in some cases, were even lower in price. Similar prices were negotiated with laboratories for CD4/CD8 and viral load tests.

PAAL coordinated with donors and stakeholders to quantify and report requirements for rapid HIV Test kits, for PMTCT programmes in the Rift Valley and coastal regions of Kenya. .  This allowed employers to offer care and support to patients’ families and commodities at free or subsidized cost. These partner organizations, still run comprehensive wellness programs to date, that extend beyond HIV to include non-communicable diseases like diabetes, hypertension and cancers.

Companies see the benefits of providing anti-retroviral therapy to those in need to ensure productivity and good health. . Employers can now provide healthcare and medical insurance, and the provision of workplace ART. Monthly costs for fixed dose combinations of ARV drugs is now US$15 compared to well over USD 1,000.00 when PAAL was launched in 2001.